Article info
PDFCommentary
Philanthropy on trial: can the rich rescue shelved compounds?
- Correspondence to Prof Effy Vayena, Institute of Biomedical Ethics, University of Zurich, Zurich, Switzerland; effy.vayena{at}uzh.ch
Citation
Philanthropy on trial: can the rich rescue shelved compounds?
Publication history
- Received June 16, 2017
- Accepted July 11, 2017
- First published August 3, 2017.
Online issue publication
October 25, 2017
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Other content recommended for you
- A Plutocratic Proposal: an ethical way for rich patients to pay for a place on a clinical trial
- Donor-funded research: permissible, not perfect
- Acceptability of donor funding for clinical trials in the UK: a qualitative empirical ethics study using focus groups to elicit the views of research patient public involvement group members, research ethics committee chairs and clinical researchers
- From protection to entitlement: selecting research subjects for early phase clinical trials involving breakthrough therapies
- Biomedical conflicts of interest: a defence of the sequestration thesis—learning from the cases of Nancy Olivieri and David Healy
- Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials
- The role of clinical trials in the sustainability of the Italian national health service cancer drug expenditure
- Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries
- Towards the patient revolution
- Engaging African ancestry participants in SLE clinical trials